Prevalence of Obstructive Sleep Apnea (OSA) is reported as 23% in T2DM. OSA and T2DM share a bidirectional relationship, the effects of which are exacerbated by obesity, a common, shared comorbidity. Diagnosis and treatment improve glycemic, CV, and other outcomes, including mortality. Therefore, ADA recommends screening for OSA at least annually as part of routine care in DM. Polysomnography, the gold standard for diagnosing OSA is cumbersome, expensive, resource intensive, and impractical to implement in daily clinical practice. The STOP-Bang questionnaire is a validated, 8 question, easy-to-use, reliable screening tool for OSA. A score ≥ 3 has sensitivity 93% and 100% to detect moderate-severe and severe OSA respectively. Risk scoring is as in fig 1. High risk can also be scored as YES to 2 or more STOP questions AND male gender/BMI > 35/neck circumference > 40cm. We present screening data and highlight the prevalence of OSA in T2DM in routine clinical practice. Median age 55, median BMI 26.03, male 55%. From this screening n=1358 (58.94%) have intermediate or high risk of OSA and should be further investigated with polysomnography. Our data suggest that intermediate to high risk of OSA occurs at a lower BMI (26) in the population screened, with a majority (91%) having a neck circumference <40cm, and highlights the need to screen for OSA rigorously in daily clinical practice, even in people that would otherwise have been “eye-balled” as low risk

Disclosure

U.Ayyagari: None. R.Rp: None. M.Krishnamoorthy: None. B.Jaganmohan: None. S.Aswathiah: None. B.Karuppan: None. S.Pandian: None. K.Dash: None. S.Yr: None. D.M.Madhavdas: Speaker's Bureau; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk, Sanofi. V.S: None. N.Nk: n/a. K.Seshadri: Speaker's Bureau; Abbott, Biocon, Boehringer Ingelheim International GmbH, Cipla Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis AG, Novo Nordisk, USV Private Limited. M.Rm: None. K.Natarajan: None. B.S.Thumala: None. R.Selvarajan: None. R.S.Erukulapati: None. S.Das: n/a. S.Duvuru: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.